Acadia Submits Supplemental New Drug Application for Nuplazid to Treat Dementia-related Psychosis, Hallucinations
Acadia Pharmaceuticals announced it has submitted a supplemental new drug application (sNDA) to the U.S. Food and Drug Administration for a new indication for Nuplazid (pimavanserin) in the treatment of hallucinations and delusions associated with dementia-related psychosis. Dementia affects approximately 8 million people in the U.S. and is…